NEW YORK (GenomeWeb News) – Sequenta has completed a Series C financing round, raising $20 million, it said on Tuesday.

Proceeds will go toward the commercial scale-up and clinical validation of its next-generation sequencing-based ClonoSight Test for minimal residual disease in leukemia and lymphoma.

Foresite Capital Management led the round, and all inside investors participated, Sequenta said, including MDV and Index Ventures. In addition, Jim Tananbaum, managing director of Foresite Capital, has joined Sequenta's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.